DBV Technologies’ (DBVT) “Market Outperform” Rating Reiterated at JMP Securities

JMP Securities reiterated their market outperform rating on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Friday,Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

A number of other equities analysts have also commented on DBVT. HC Wainwright increased their price target on DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. StockNews.com assumed coverage on DBV Technologies in a research note on Thursday. They issued a “hold” rating for the company.

DBV Technologies Price Performance

Shares of DBV Technologies stock opened at $4.97 on Friday. The stock has a 50 day moving average of $3.32 and a 200 day moving average of $3.81. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $9.49.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.